Poly-L-histidine downregulates fibrinolysis

Blood Coagulation and Fibrinolysis

Volumn 14, Issue 7, 2003, Pages 627-632

  Chu, Arthur J ^a,b   Mathews, Suresh T ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b 416 Lande Medical Research Building ^*  (United States)

Author keywords

Fibrinolysis; Plasmin; Plasminogen activation; Poly L histidine; Thrombosis

Indexed keywords

ENZYME PRECURSOR; FIBRIN; FIBRINOGEN; GLYCOPROTEIN; POLYHISTIDINE; THROMBIN; UROKINASE;

ARTICLE; DOWN REGULATION; FIBRIN FORMATION; FIBRIN POLYMERIZATION; FIBRINOLYSIS; HUMAN; IN VITRO STUDY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RISK FACTOR; THROMBOPHILIA; TURBIDITY;

DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FIBRIN; FIBRINOLYSIS; HISTIDINE; HUMANS; KINETICS; MOLECULAR MIMICRY; NEPHELOMETRY AND TURBIDIMETRY; PLASMIN; PROTEIN BINDING; PROTEINS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0142187200     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200310000-00002     Document Type: Article

References (24)

1. Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46:103-112.
2. Camerer E, Kolsto A-B, Prydz H. Cell biology of tissue factor, the principal indicator of blood coagulation. Thromb Res 1996; 81:1-41.
3. Hollander IJ. Plasminogen activators and their potential in therapy. Crit Rev Biotech 1987; 6:253-271.
4. Henkin J, Marcotte P, Yang HC. The plasminogen-plasmin system. Prog Cardiovasc Dis 1991; 34:135-164.
5. Whiteman T, Hassouna HI. Hypercoagulable states. Hematol Oncol Clin North Am 2000; 14:355-377.
6. Osterud B, Bjorklid E. Tissue factor pathway in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27:605-617
7. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 116:754-761.
8. Broekmans AW. Hereditary protein C deficiency. Hemostasis 1985; 15:233-240.
9. Dahlback B. New molecular insight into the genetics of thrombophilia: resistance to activated protein C caused by Arg 506 to Gln mutation in factor V as a pathogenic risk for venous thrombosis. Thromb Haemost 1995; 74:139-148.
10. Thomas RH. Hypercoagulability syndromes. Arch Intern Med 2001; 161:2433-2439.
11. Brandt JT. Plasminogen and tissue type plasminogen activator deficiency as risk factors for thromboembolism diseases. Arch Pathol Lab Med 2002; 126:1376-1381.
12. Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 1996; 28:371-380.
13. Engesser L, Kluft C, Briet E, Brommer EJP. Familial elevation of plasma histidine-rich glycoprotein in a family with thrombophilia. Br J Haematol 1976; 67:355-358.
14. Lijnen HR, Hoylaerts M, Collen D. Isolation and characterization of a human plasma protein with affinity for the lysine-binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. J Biol Chem 1980; 255:10214-10222.
15. Leung LLK. Interaction of histidine-rich glycoprotein with fibrinogen and fibrin. J Clin Invest 1986; 77:1305-1311
16. Soeda S, Sakaguchi A, Shimeno H, Nagamatsu A. Fibrinolysis and anticoagulant activities of highly sulfated fucoidan. Biochem Pharmacol 1992; 43:1853-1858.
17. Choi KS, Ghuman J, Kassam G, Kang HM, Fitzpatrick SL, Waisman DM. Annexin II tetramer inhibits plasmin-dependent fibrinolysis. Biochemistry 1998; 37:648-655.
18. Szabo GC, Pozsgay M, Elodi P. Investigation of the substrate-binding site of human plasmin using tripeptidy-p-nitroanilide substrates. Thromb Res 1980; 20:199-206.
19. Schmidt RJ, Myers AM, Gillham NW, Boynton JE. Immunological similarities between specific chloroplast ribosomal proteins from Chlamydomonas reinhardtii and ribosomal proteins from Escherichia coli. Mol Biol Evol 1984; 1:317-334.
20. Cesarman GM, Guevara CA, Haijar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (tPA): II annexin II-mediated enhancement of tPA-dependent plasminogen activation. J Biol Chem 1994; 269:21198-21203
21. Kassam G, Choi KS, Ghuman J, Kang HM, Fitzpatrick SL, Zackson T, et al. The role of annexin II tetramer in the activation of plasminogen. J Biol Chem 1998; 273:4790-4799.
22. Choi KS, Fitzpatrick SL, Filipenko NR, Fogg DK, Kassam G, Magliocco AM, Waisman DM. Regulation of plasmin-dependent fibrin clot lysis by annexin II heterotetramer. J Biol Chem 2001; 276:25212-25221.
23. Fitzpatrick SL, Kassam G, Choi KS, Kang HM, Fogg DK, Waisman DM. Regulation of plasmin activity by annexin II tetramer. Biochemistry 2000; 39:1021-1028.
24. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273:27176-27181.